Roland Kozlowski, PhD

Roland Kozlowski received a first class honours degree from the University of Bath and a PhD from the University of Cambridge. He is a bioentrepreneur who has worked in the industry for approaching two decades. Roland has held a number of operational roles including most recently Chief Executive Officer and a founder of Lectus Therapeutics Limited (investor exit via asset sale to UCB in Q4, 2011), Chief Executive Officer and co-founder of Sense Proteomic Limited (trade sale to Procognia Limited in Q1, 2003). In the mid 1990s Roland worked with Oxford Molecular PLC on their cornerstone deal he negotiated with Yamanouchi Pharmaceutical Co., Ltd. During his career Roland has gained considerable transactional experience ranging from company sale, purchase, financing and in- and out-licensing and commercialisation of technology. In the past Roland ran a Research Groups at the University of Oxford and University of Bristol where subsequently he was a Visiting Industrial Professor.  He has published and patented in the field of ion channel physiology and pharmacology. Roland has served on the boards of a number of companies including the Bio-Industry Association in the UK.  Roland is presently non-executive director of London Genetics which operates in the personalised medicine space, Chief Strategy Officer of BTM Mazowsze Sp. z o. o. a company set up to commercialize innovation emerging from the leading life science research institutions in Warsaw and President and owner of Life Science Biznes Consulting (LSBC) Sp. z o. o. a Central European Strategic Advisory Firm.